These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 27180831)
21. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756 [TBL] [Abstract][Full Text] [Related]
22. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Lee YH; Bae SC Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847 [TBL] [Abstract][Full Text] [Related]
23. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S Pharmacogenomics J; 2016 Apr; 16(2):147-50. PubMed ID: 25896534 [TBL] [Abstract][Full Text] [Related]
24. Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. Iwaszko M; Świerkot J; Kolossa K; Jeka S; Wiland P; Bogunia-Kubik K Joint Bone Spine; 2016 Jan; 83(1):75-9. PubMed ID: 26453102 [TBL] [Abstract][Full Text] [Related]
25. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748 [TBL] [Abstract][Full Text] [Related]
26. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Pavy S; Toonen EJ; Miceli-Richard C; Barrera P; van Riel PL; Criswell LA; Mariette X; Coenen MJ Ann Rheum Dis; 2010 Jun; 69(6):1022-8. PubMed ID: 19966089 [TBL] [Abstract][Full Text] [Related]
27. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Li N; Betts KA; Messali AJ; Skup M; Garg V Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087 [TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. Gilani SS; Nair N; Plant D; Hyrich K; Morgan AW; Morris AP; Wilson AG; Isaacs JD; Barton A; Bluett J; Pharmacogenomics; 2020 Nov; 21(16):1151-1156. PubMed ID: 33124499 [No Abstract] [Full Text] [Related]
29. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989 [TBL] [Abstract][Full Text] [Related]
30. Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Bek S; Bojesen AB; Nielsen JV; Sode J; Bank S; Vogel U; Andersen V Pharmacogenomics J; 2017 Oct; 17(5):403-411. PubMed ID: 28607508 [TBL] [Abstract][Full Text] [Related]
32. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Bowes JD; Potter C; Gibbons LJ; Hyrich K; Plant D; Morgan AW; Wilson AG; Isaacs JD; Worthington J; Barton A; Pharmacogenet Genomics; 2009 Apr; 19(4):319-23. PubMed ID: 19262425 [TBL] [Abstract][Full Text] [Related]
33. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Canet LM; Sánchez-Maldonado JM; Cáliz R; Rodríguez-Ramos A; Lupiañez CB; Canhão H; Martínez-Bueno M; Escudero A; Segura-Catena J; Sorensen SB; Hetland ML; Soto-Pino MJ; Ferrer MA; García A; Glintborg B; Filipescu I; Pérez-Pampin E; González-Utrilla A; Nevot MÁL; Conesa-Zamora P; Broeder AD; De Vita S; Jacobsen SEH; Collantes-Estevez E; Quartuccio L; Canzian F; Fonseca JE; Coenen MJH; Andersen V; Sainz J Pharmacogenomics J; 2019 Feb; 19(1):83-96. PubMed ID: 30287909 [TBL] [Abstract][Full Text] [Related]
34. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
35. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Ferreiro-Iglesias A; Montes A; Perez-Pampin E; Cañete JD; Raya E; Magro-Checa C; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Joven B; Carreira P; Balsa A; Pascual-Salcedo D; Blanco FJ; Moreno-Ramos MJ; Fernández-Nebro A; Ordóñez MC; Alegre-Sancho JJ; Narváez J; Navarro-Sarabia F; Moreira V; Valor L; García-Portales R; Marquez A; Martin J; Gómez-Reino JJ; Gonzalez A Pharmacogenomics J; 2016 Apr; 16(2):137-40. PubMed ID: 25896535 [TBL] [Abstract][Full Text] [Related]
36. Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis. Gu KN; Bang SY; Lee HS; Park Y; Kang JY; Kim JS; Nam B; Yoo HS; Shin JM; Lee YK; Lee TH; Chun S; Cho SK; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Kim K; Bae SC Arthritis Res Ther; 2019 Aug; 21(1):195. PubMed ID: 31462329 [TBL] [Abstract][Full Text] [Related]
37. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. Lopez-Rodriguez R; Perez-Pampin E; Marquez A; Blanco FJ; Joven B; Carreira P; Ferrer MA; Caliz R; Valor L; Narvaez J; Cañete JD; Ordoñez MDC; Manrique-Arija S; Vasilopoulos Y; Balsa A; Pascual-Salcedo D; Moreno-Ramos MJ; Alegre-Sancho JJ; Navarro-Sarabia F; Moreira V; Garcia-Portales R; Raya E; Magro-Checa C; Martin J; Gomez-Reino JJ; Gonzalez A PLoS One; 2018; 13(5):e0196793. PubMed ID: 29734345 [TBL] [Abstract][Full Text] [Related]
38. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827 [TBL] [Abstract][Full Text] [Related]
39. Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Guan Y; Zhang H; Quang D; Wang Z; Parker SCJ; Pappas DA; Kremer JM; Zhu F Arthritis Rheumatol; 2019 Dec; 71(12):1987-1996. PubMed ID: 31342661 [TBL] [Abstract][Full Text] [Related]
40. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S PLoS One; 2015; 10(4):e0122088. PubMed ID: 25848939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]